Current status of ctDNA in precision oncology for hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research

Jingjing Li¹  Jianye Wu¹  Yan Li¹  Weiqi Dai¹  Jie Ji²  Jiao Feng²  Chuanyong Guo²  Liwei Wu²  Qiang Yu²  Yuanyuan Zheng² 

[1] Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine;Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine;

关键词: ctDNA;    Hepatocellular carcinoma;    Mutation;    Methylation;   

DOI  :  10.1186/s13046-021-01940-8

来源: DOAJ

【 摘 要 】

Abstract The conventional method used to obtain a tumor biopsy for hepatocellular carcinoma (HCC) is invasive and does not evaluate dynamic cancer progression or assess tumor heterogeneity. It is thus imperative to create a novel non-invasive diagnostic technique for improvement in cancer screening, diagnosis, treatment selection, response assessment, and predicting prognosis for HCC. Circulating tumor DNA (ctDNA) is a non-invasive liquid biopsy method that reveals cancer-specific genetic and epigenetic aberrations. Owing to the development of technology in next-generation sequencing and PCR-based assays, the detection and quantification of ctDNA have greatly improved. In this publication, we provide an overview of current technologies used to detect ctDNA, the ctDNA markers utilized, and recent advances regarding the multiple clinical applications in the field of precision medicine for HCC.

【 授权许可】

Unknown